

San Francisco

Spring Group Meeting

SPECIALS

Lymphoma Committee

Lymphoma Committee

Leadership

Chair: Jonathan W. Friedberg, MD
 Vice-Chair: Sonali M. Smith, MD
 Executive Officer: Susan M. O'Brien, MD
 Statisticians: Michael LeBlanc, PhD
 Hongli Li, MS
 Shay Bellasea, MS
 Matt Chansky, BS

Scientific Leadership

Translational Medicine: Alexey Danilov, MD, PhD
 Radiation Oncology: Nicholas Burden Figura, MD
 Imaging: Lawrence H. Schwartz, MD
 Immunotherapeutics: Sweetha Kambhampati, MD
 Pathology: Joo Y. Song, MD
 Early Therapeutics: Nasheed Mohammad Hossain, MD

Designates

Cancer Control: Hayder Saeed, MD
 Digital Engagement: Elizabeth A. G. Brem, MD
 Veterans Affairs: Helen Ma, MD
 Data Coordinators: Alex Rangel, BS
 Gabi Herbert, MS, BS
 Laura Wells, BA
 Daria Chugina, MD, CCRPS
 Oncology Research Professionals:
 CRA: Erin M. Cebula, MPH
 Jacob Kedroske, BA
 Nurse: TBD
 Patient Advocate: Tricia Hernandez, MS
 Pharmaceutical Science: Martina Fraga, PharmD
 Protocol Project Manager: Erin Rogers
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Saturday, May 3, 2025 12:00 p.m. - 2:00 p.m.
 Room: Garden Room (Atrium Lobby Level)

Agenda

1. **Welcome & Introductions** - Dr. Jonathan Friedberg & Dr. Sonali Smith
2. **High Risk/Transformed Indolent Lymphomas Mini-Symposium**
 - a. Overview of high risk follicular lymphoma - Dr. Swetha Thiruvengadam
 - b. Richter Transformation - Dr. Mazyar Shadman
 - c. Relapsed high risk follicular lymphoma: early results of S1608 - Dr. Paul Barr
 - d. Discussion and questions from audience - Panel Discussion

3. S1826 ctDNA Update - Dr. Herrera

4. Patient Advocacy Report - Tricia Hernandez

5. New Trials

- a. EA4232 - Dr. Hoffman

6. Ongoing Trials

- | | |
|-------------|--------------------------|
| a. S2308 | Dr. Ghosh |
| b. S2114 | Dr. Hess |
| c. S1925 | Dr. Stephens |
| d. S2207 | Drs. Amengual and Reagan |
| e. AHOD2131 | Dr. Hu |
| f. AO51902 | Dr. Amengual |
| g. AO52101 | Dr. Phillips |
| h. ANHL1931 | Dr. Kamdar |
| i. S1918 | Dr. Brem |

Developing Studies

S2506, "MOZART MZL: A Randomized 3-Arm Phase II Study Evaluating Mosunetuzumab Alone and In Combination with Either Zanubrutinib or Polatuzumab Vedotin for The Treatment of Patients with Relapsed/Refractory Marginal Zone Lymphoma." Drs. Hu and Smith.

Open Studies

S1918, "A Phase II/III Randomized Study of R-miniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. Brem and Smith. Activated: 3/19/21.

S2214, "A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma." Drs. Hess and Hossain. Activated: 2/23/2023.

S2207, "Randomized phase II study of the addition of Targeted therapeutic agents to tafasitamab-based therapy in non-transplant-eligible patients with Relapsed/refractory Large B-cell Lymphoma." Drs. Amengual, Reagan, and Smith. Activated: 6/30/2023

S2308, "Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma." Drs. Ghosh and Friedberg. Activated: 8/1/2024

Lymphoma Committee

CTSU/EA4151, "A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission." Dr. Fenske. SWOG Champion: Dr. Till. Activated: 8/29/17.

CTSU/ANHL1931, "A Randomized Phase 3 trial of Nivolumab in Combination with Chemo immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B cell Lymphoma." Dr. Roth. SWOG Champion: Dr. Kamdar. Activated 6/7/2021.

CTSU/A051902, "A Randomized Phase II Study of CHO(E)P vs Oral Azacitidine-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas." Dr. Mehta-Shah. SWOG Champion: Dr. Amengual. Activated 7/30/2021.

CTSU/A052101, "A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON)." Dr. Beaven. SWOG Champion: Dr. Tycel. Activated 09/08/2023.

CTSU/AHOS2131, "A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma." Dr. Henderson. SWOG Champion: Dr. Hu. Activated 04/28/2023.

Closed Studies

S1608, "Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma." Drs. Barr and Burack. Activated: 8/10/17. Closed: 7/15/2024

CTSU/A051701, "Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas." Dr. Abramson. SWOG Champion: Dr. Vallurupalli. Activated: 8/7/19. Closed: 12/14/2023.

CTSU/EA4181, "A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CA-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients <= 70 years Old with Untreated Mantle Cell Lymphoma." Dr. Wagner-Johnson. SWOG Champion: Dr. Spurgeon. Activated: 10/3/19. Closed: 4/7/2023

Open Leukemia Studies

S1925, "A Randomized, Phase III Study of Early Intervention with

Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study." Dr. Stephens. Activated: 12/14/20.

S1905, "A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)." Drs. Advani and Papadantonakis. Activated: 8/17/20.

Developing Leukemia Studies

S2504, "A Randomized Phase II Study of Pirtobrutinib Plus R-CHOP vs. R-CHOP for Patients with Previously Untreated Richter Transformation (RT)." Drs. M. Shadman, D. Stephens, and A. Danilov.

Open Cancer Care Delivery Study

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Dr. Shankaran. Activated 7/26/2021.

Publications

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Fall 2024 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts.

Published/Accepted Manuscripts

S1826 Nivolumab-AVD or Standard of Care in Advanced Stage Classic Hodgkin Lymphoma. Herrera A, LeBlanc M, Castellino S, Li H Rutherford S, Evens A, Davison K, Punnett A, Parsons S, Ahmed S, Casulo C, Bartlett N, Tuscano J, Mei M, Hess B, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lambale A, Kumar P, Chowdury S, Brinker B, Sharma N, Singh A, Blum K, Perry A, Kovach A, Hodgson D, Constine L, Kostakoglu Shields L, Prica A, Dillon H, Little R, Shipp M, Crump M, Kahl B, Leonard J, Smith S, Song J, Kelly K, Friedberg JW. New England Journal of Medicine Oct 17;391(15):1379-1389, 2024.

<https://pubmed.ncbi.nlm.nih.gov/39413375/>

S1826 Pediatric and Adolescent Hodgkin Lymphoma: Paving the Way for Standards of Care and Shared Decision Making. Kahn J, Mauz-Korholz C, Hernandez T, Milgrom S, Castellino S. ASCO Educational Book, 2024.

https://ascopubs.org/doi/10.1200/EDBK_432420

Lymphoma Committee

S2308 SWOG 2308: Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma. Ghosh N, Bellasea S, Li H, Olszewski A, Bryan L, Danilov A, Smith S, LeBlanc M, Friedberg JW. Accepted.

A51101 Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101. Batchelor TT, Giri S, Ruppert AS, Geyer SM, Smith SE, Mohile N, Swinnen LJ, Friedberg JW, Kahl BS, Bartlett NL, Hsi ED, Cheson BD, Wagner-Johnston N, Nayak L, Leonard JP, Rubenstein JL. Blood Adv Jun 25;8(12):3189-3199, 2024. <https://pubmed.ncbi.nlm.nih.gov/38598710/>

Multiple Studies Radiation target nomenclature for lymphoma trials: consensus recommendations from the National Clinical Trials Network groups. Saifi O, Pinnix C, Ballas L, Kelsey C, Milgrom S, Terezakis S, Figura N, Parikh R, Grecula J, lampouri S, Ha C, Lo A, Plataras J, Hodgson D, Hoppe. Lancet Haematol Dec;11(12):e951-e958, 2024. <https://pubmed.ncbi.nlm.nih.gov/39362223/>

Submitted Manuscripts

S1826 Castellino S, Li H, Herrera A, Punnett A, LeBlanc M, Parsons S, Hodgson D, Keller F, Drachtman R, Lamble A, Forlenza C, Doan A, Rutherford S, Evens A, Little R, Smith M, Hoppe B, Song J, Smith S, Friedberg J, Kelly K. Nivolumab-AVD is superior to Brentuximab Vedotin-AVD with 2-year follow-up of S1826 in Adolescent Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL). Submitted.

S1826 Rutherford S, Li H, Herrera A, LeBlanc M, Ahmed S, Davison K, Parsons S, Unger J, Perry A, Casulo C, Bartlett N, Tuscano J, Hess B, Torka P, Kumar P, Jacobs R, Song J, Castellino S, Kahl B, Leonard J, Smith S, Friedberg J, Evens A. Nivolumab-AVD versus brentuximab vedotin-AVD in older patients with advanced stage classic Hodgkin lymphoma. Submitted.

A051301 Ibrutinib With Autologous Transplant In Relapsed/Refractory Activated B-Cell Type Diffuse Large B-Cell Lymphoma (ABC DLBCL). Andreadis C, Bobek O, His E, Fenske T, Stiff P, Hill B, Geyer S, Horwitz M, Khimani F, Little R, Dinner S, Friedberg JW, Kahl B, Perales M, Devine S, Leonard J, Bartlett N. Submitted.

Lymphoma Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	S1608	S1918	S2114	S2207	S2308	A051701	A051902
Banner University Medical Center - Tucson	2	-	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	1	2	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	3	-	-	-	8	-
Cancer Research Consortium of West Michigan NCORP	3	-	5	-	-	-	-
Cancer Research for the Ozarks NCORP	1	1	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	2	-	3	-	-	-
Cedars-Sinai Medical Center	-	1	-	4	-	-	-
City of Hope Comprehensive Cancer Center	8	10	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	6	5	1	-	-	1
Columbus NCI Community Oncology Research Program	1	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	7
Froedtert and the Medical College of Wisconsin LAPS	-	-	3	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	2	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	2	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	1	-	-	-	-	-
Heartland Cancer Research NCORP	1	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	2	-
Kaiser Permanente NCI Community Oncology Research Program	3	3	-	-	-	-	-
Loyola University Medical Center	-	-	2	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	2	3	19	-	-	3	-
Michigan Cancer Research Consortium NCORP	1	8	-	1	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	1	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	1	-
Northwestern University LAPS	1	-	-	-	-	-	-
Oregon Health and Science University	-	-	2	-	-	2	-
Pacific Cancer Research Consortium NCORP	-	-	6	1	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	4	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	7	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-
University of Alabama at Birmingham/Deep South Research Consortium LAPS	-	-	-	-	-	3	-
University of Arkansas for Medical Sciences	-	-	5	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	1
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	1	-	3	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	1	-	-	-	-
University of Rochester LAPS	16	-	7	7	1	11	3
University of Texas Health Science Center at San Antonio	-	-	9	1	4	-	-
University of Texas MD Anderson Cancer Center LAPS	3	-	-	-	1	-	-
University of Utah - Huntsman Cancer Institute LAPS	1	11	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	1	1	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	1	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	1	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-
ALLIANCE	17	37	17	5	5	-	-
ECOG-ACRIN	5	17	7	-	1	-	-
NRG	11	7	5	4	-	-	-
Total	78	124	98	27	15	34	12

Lymphoma Committee

Accrual from trials that are open as of 12/31/2024 or have closed in the prior 18 Months by Institution and Study

	A052101	AH02131	ANHL1931	E4412	EA4151
Banner University Medical Center - Tucson	-	-	-	-	1
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	23
Cancer Research Consortium of West Michigan NCORP	-	1	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-
Cedars-Sinai Medical Center	-	3	1	-	-
City of Hope Comprehensive Cancer Center	-	9	11	-	18
Columbia University Minority Underserved NCORP	-	1	3	1	-
Columbus NCI Community Oncology Research Program	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	15
Froedtert and the Medical College of Wisconsin LAPS	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	3	-	11	-
Loyola University Medical Center	-	-	-	-	5
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	2
Michigan Cancer Research Consortium NCORP	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	1	-	2
Nevada Cancer Research Foundation NCORP	-	-	-	1	-
Northwell Health NCORP	-	-	-	-	-
Northwestern University LAPS	-	-	1	-	-
Oregon Health and Science University	-	3	-	-	7
Pacific Cancer Research Consortium NCORP	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	2	-	-
UC San Diego Moores Cancer Center	-	-	-	-	1
University of Alabama at Birmingham/Deep South Research Consortium LAPS	-	-	-	7	5
University of Arkansas for Medical Sciences	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	2
University of Kansas Cancer Center - MCA Rural MU NCORP	2	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	3
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-
University of Rochester LAPS	11	7	10	-	11
University of Texas Health Science Center at San Antonio	-	1	-	-	14
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	4	-	-	20
Upstate Carolina Consortium Community Oncology Research Program	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	1
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	1	-	-	-	5
ALLIANCE	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-
NRG	-	-	-	-	-
Total	14	32	29	20	135

